Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.

Ferjan S, Janez A, Jensterle M

Metabolic syndrome and related disorders24 Oct 2017Cited by 28 (Europe PMC)

PMID29064743DOI10.1089/met.2017.0095PepBankPUB-29064743

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS previously treated with liraglutide, sitagliptin plus metformin limited weight regain to 0.9 kg, versus 4.7 kg with metformin alone.
In plain wordsIn obese women with PCOS who had stopped liraglutide, sitagliptin plus metformin led to less weight regain than metformin alone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change over 12 weeks
Study
n = 24
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
weight regain
4.7 kg
metformin alone
weight regain
0.9 kg
sitagliptin plus metformin
Source sentences
Summary
Women treated with MET regain 4.7 ± 2.7 kg (P = 0.002) compared with a 0.9 ± 2.5 kg in COMBO (P = 0.147).
3 context sentences(design, population, supporting numbers)
Summary · context
The between-treatment differences were significant for weight change (P < 0.001), percentage of weight change (P < 0.001), and BMI change (P < 0.001).
Summary · context
A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m², mean ± standard deviation).
Summary · context
They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2906474301
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS previously treated with liraglutide, BMI rose by 0.3 kg/m2 with sitagliptin plus metformin, versus 1.7 kg/m2 with metformin alone.
In plain wordsIn obese women with PCOS who had stopped liraglutide, BMI rose less with sitagliptin plus metformin than with metformin alone.
Peptide
Liraglutide
Outcome
DecreaseBMI change over 12 weeks
Study
n = 24
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI increase
1.7 kg/m2
metformin alone
BMI increase
0.3 kg/m2
sitagliptin plus metformin
Source sentences
Summary
BMI increased for 1.7 ± 0.9 kg/m² in MET (P = 0.002) compared with 0.3 ± 0.8 kg/m² increase in COMBO (P = 0.136).
3 context sentences(design, population, supporting numbers)
Summary · context
The between-treatment differences were significant for weight change (P < 0.001), percentage of weight change (P < 0.001), and BMI change (P < 0.001).
Summary · context
A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m², mean ± standard deviation).
Summary · context
They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2906474302
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS previously treated with liraglutide, body weight regain was 0.8% with sitagliptin plus metformin, versus 4.5% with metformin alone.
In plain wordsIn obese women with PCOS who had stopped liraglutide, sitagliptin plus metformin led to a smaller percentage of weight regain than metformin alone.
Peptide
Liraglutide
Outcome
DecreasePercentage body weight regain
Study
n = 24
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
percentage weight regain
4.5%
metformin alone
percentage weight regain
0.8%
sitagliptin plus metformin
Source sentences
Summary
MET group regain 4.5% ± 2.5% of body weight as opposed to 0.8% ± 2.6% in COMBO.
3 context sentences(design, population, supporting numbers)
Summary · context
The between-treatment differences were significant for weight change (P < 0.001), percentage of weight change (P < 0.001), and BMI change (P < 0.001).
Summary · context
A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m², mean ± standard deviation).
Summary · context
They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2906474303
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In obese women with PCOS previously treated with liraglutide, the sitagliptin plus metformin group showed greater ability to resist emotional eating.
In plain wordsIn obese women with PCOS who had stopped liraglutide, those on sitagliptin plus metformin were better able to resist emotional eating.
Peptide
Liraglutide
Outcome
IncreaseAbility to resist emotional eating
Study
n = 24
Comparator
Metformin alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Greater ability to resist emotional eating was demonstrated in COMBO.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m², mean ± standard deviation).
Summary · context
They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2906474304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.